Skip to content
mapperlab
← Dashboard
Stock

CYTK

CYTOKINETICS INC
Health CareBiotechnologyLatest close $756 of 27 marquee funds currently hold2 CUSIPs mapped
Current holders
6
27 funds tracked
Ever held
7
Current + past
New this quarter
1
Exited this quarter
1

Marquee-fund ownership over time

Aug 9, 2024Feb 14, 2025Nov 14, 2025May 15, 2026
Now
7

This quarter's activity

New positions opened

Positions exited

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Citadel Advisors$56$75+35%
Two Sigma Investments re-entered$56$75+35%
D.E. Shaw re-entered$0.00$75—
AQR Capital Management$56$75+35%
Millennium Management re-entered$0.00$75—
Point72 Asset Management re-entered$56$75+35%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
Renaissance Technologies→ $79+41%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at CYTOKINETICS INC. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
16
Filings · last 90d
47
Total on file
612
Recent SEC buffer
Most recent
Jun 9, 2026

30d / 90d windows measured from Jun 9, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 612 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · CYTOKINETICS INC

Annual figures sourced directly from CYTOKINETICS INC's 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$88.04M
FY2025+377% YoY
Net income
-$784.96M
FY2025-33% YoY
EPS (diluted)
$-6.54
FY2025-24% YoY
Free cash flow(?)
-$534.82M
FY2025-34% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for CYTOKINETICS INC — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
Point72 Asset ManagementQ2 2026open$76$75-1%
Two Sigma InvestmentsQ1 2026open$67$75+13%
Two Sigma InvestmentsQ1 2026open$0.00—+0%
Point72 Asset ManagementQ4 2025Q1 2026$66$67+0%
D.E. ShawQ2 2025open$30$75+152%
Two Sigma InvestmentsQ1 2025Q2 2025$0.00—+0%
D.E. ShawQ4 2024Q1 2025$55$46-16%
Millennium ManagementQ4 2024open$55$75+37%
Citadel AdvisorsQ3 2024open$56$75+35%
Two Sigma InvestmentsQ3 2024Q3 2025$56$39-31%
D.E. ShawQ3 2024Q1 2025$0.00—+0%
AQR Capital ManagementQ3 2024open$56$75+35%
Millennium ManagementQ3 2024Q1 2025$0.00—+0%
Point72 Asset ManagementQ3 2024Q3 2025$56$39-31%
Point72 Asset ManagementQ3 2024Q4 2025$0.00—+0%
Renaissance TechnologiesQ3 2024Q2 2026$56$79+41%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.